07.23.09
Bristol-Myers Squibb 2Q
2Q Revenues: $5.4 billion (+3%)
2Q Earnings: $1.3 billion (+29%)
YTD Revenues: $10.4 million (+3%)
YTD Earnings: $2.2 billion (+17%)
Comments: Revenues were up 8% excluding foreign exchange impact. Biopharmaceutical sales were $4.7 billion in the quarter (+4%). Plavix sales were $1.5 billion (+11%). Abilify sales were $643 million (+22%). Baraclude sales were $179 million (+32%). Sustiva franchise sales were $312 million (+11%). Reyataz sales were $331 million (+2%). Orencia and Sprycel sales were up 40% and 41% to $148 million and $107 million, respectively. Erbitux sales were down 12% to $173 million. R&D expenses were flat at $781 million in the quarter.
View BMS in Contract Pharma's Top Companies Report:
http://contractpharma.com/articles/2009/07/bristolmyers-squibb
Sign up today for Contracting & Outsourcing 2009!
www.contractpharma.com/2009conference
2Q Revenues: $5.4 billion (+3%)
2Q Earnings: $1.3 billion (+29%)
YTD Revenues: $10.4 million (+3%)
YTD Earnings: $2.2 billion (+17%)
Comments: Revenues were up 8% excluding foreign exchange impact. Biopharmaceutical sales were $4.7 billion in the quarter (+4%). Plavix sales were $1.5 billion (+11%). Abilify sales were $643 million (+22%). Baraclude sales were $179 million (+32%). Sustiva franchise sales were $312 million (+11%). Reyataz sales were $331 million (+2%). Orencia and Sprycel sales were up 40% and 41% to $148 million and $107 million, respectively. Erbitux sales were down 12% to $173 million. R&D expenses were flat at $781 million in the quarter.
View BMS in Contract Pharma's Top Companies Report:
http://contractpharma.com/articles/2009/07/bristolmyers-squibb
Sign up today for Contracting & Outsourcing 2009!
www.contractpharma.com/2009conference